Effects of pneumococcal conjugate vaccines on reducing the risk of respiratory disease associated with coronavirus infection

Pneumonia

Review

Marta C. Nunes¹  Eileen M. Dunne²  Bradford D. Gessner²  Christian Theilacker²  Mary P. E. Slack³ 

[1] Center of Excellence in Respiratory Pathogens, Hospices Civils de Lyon and Centre International de Recherche en Infectiologie (CIRI) Inserm U1111, CNRS UMR5308, ENS de Lyon, Université Claude Bernard, Lyon 1, Lyon, France;South African Medical Research Council, Vaccines & Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa;Pfizer Vaccines, Collegeville, PA, USA;School of Medicine & Dentistry, Griffith University, Gold Coast Campus, Southport, QLD, Australia;

关键词: Pneumococcal conjugate vaccines;    Streptococcus pneumoniae;    Pneumococcus;    Coronaviruses;    SARS-CoV-2;    COVID-19;   

DOI  :  10.1186/s41479-023-00112-w

 received in 2022-11-30, accepted in 2023-04-30,  发布年份 2023

来源: Springer

【 摘 要 】

Pneumococcal conjugate vaccines (PCVs) provide protection against vaccine-type pneumococcal disease in both children and adults. Growing evidence suggests that PCVs also reduce pneumonia and lower respiratory tract infections (LRTIs) more broadly, including protecting against viral-associated respiratory diseases. In this short narrative review, we highlight clinical studies investigating whether PCVs might have a role in reducing coronavirus disease, both those caused by endemic human coronaviruses (HCoVs) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). These studies include two randomized controlled trials assessing HCoV-associated pneumonia, one each in children and older adults, and two observational studies of PCV13 effectiveness against HCoV-associated LRTI and COVID-19 in adults. We discuss possible mechanisms for PCV protection including preventing viral pneumococcal co-infections and the possibility that pneumococci in the upper respiratory tract might modify the host immune response to SARS-CoV-2. Lastly, we identify knowledge gaps and further questions on the potential role of PCVs during the COVID-19 pandemic.

【 授权许可】

CC BY   
© The Author(s) 2023